BioLineRx Ltd. (NASDAQ:BLRX) continues its commercialization transition activities for Aphexda as responsibilities for marketing shift from BioLine’s internal team to Ayrmid’s subsidiary ...

Q4 2024 Earnings Call Transcript March 31, 2025 Operator: Ladies and gentlemen, thank you for standing by. Welcome to the ...

BLRX READ THE FULL BLRX RESEARCH REPORT BioLineRx Ltd. (NASDAQ:BLRX) reported full-year 2024 results, with revenues reaching $28.9 million. As the company completes its commercialization transition of ...

Jones Trading reiterated their hold rating on shares of BioLineRx (NASDAQ:BLRX – Free Report) in a research note published on Wednesday morning, MarketBeat.com reports. Other equities research ...

for APHEXDA ® (motixafortide) with $10 million upfront payment, up to $87 million in commercial milestones, and high double-digit royalties on net sales - - Completed financings raising combined ...